JP2021525242A5 - - Google Patents

Info

Publication number
JP2021525242A5
JP2021525242A5 JP2020565331A JP2020565331A JP2021525242A5 JP 2021525242 A5 JP2021525242 A5 JP 2021525242A5 JP 2020565331 A JP2020565331 A JP 2020565331A JP 2020565331 A JP2020565331 A JP 2020565331A JP 2021525242 A5 JP2021525242 A5 JP 2021525242A5
Authority
JP
Japan
Prior art keywords
compound
formulation
parts kit
pharmaceutically
keratitis
Prior art date
Application number
JP2020565331A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019228307A5 (https=
JP2021525242A (ja
JP7742226B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/088593 external-priority patent/WO2019228307A1/en
Publication of JP2021525242A publication Critical patent/JP2021525242A/ja
Publication of JPWO2019228307A5 publication Critical patent/JPWO2019228307A5/ja
Publication of JP2021525242A5 publication Critical patent/JP2021525242A5/ja
Application granted granted Critical
Publication of JP7742226B2 publication Critical patent/JP7742226B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565331A 2018-05-28 2019-05-27 新たな医薬品使用 Active JP7742226B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018088701 2018-05-28
CNPCT/CN2018/088701 2018-05-28
PCT/CN2019/088593 WO2019228307A1 (en) 2018-05-28 2019-05-27 New pharmaceutical use

Publications (4)

Publication Number Publication Date
JP2021525242A JP2021525242A (ja) 2021-09-24
JPWO2019228307A5 JPWO2019228307A5 (https=) 2022-06-06
JP2021525242A5 true JP2021525242A5 (https=) 2022-06-06
JP7742226B2 JP7742226B2 (ja) 2025-09-19

Family

ID=68697381

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020565331A Active JP7742226B2 (ja) 2018-05-28 2019-05-27 新たな医薬品使用

Country Status (8)

Country Link
US (2) US20210196783A1 (https=)
EP (1) EP3802562A4 (https=)
JP (1) JP7742226B2 (https=)
KR (1) KR20210016365A (https=)
CN (1) CN112236440A (https=)
MA (1) MA52794A (https=)
TW (1) TW202016127A (https=)
WO (1) WO2019228307A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020000029A (es) * 2017-07-05 2020-08-06 Jiangyin Mucocare Pharmaceutical Co Ltd Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon.
CN113613657A (zh) * 2019-01-10 2021-11-05 江阴优培尔康药业有限公司 含有白三烯受体拮抗剂的新型配制品
MX2022003057A (es) * 2019-09-14 2022-06-16 Jiangyin Usun Pharmaceutical Co Ltd Nuevos peptidos.
CA3160167A1 (en) * 2019-12-02 2021-06-10 Ming Gu Peptides and their use in the treatment of inflammation
US20230372324A1 (en) * 2020-10-13 2023-11-23 Diomed Developments Ltd. Gel formulations comprising montelukast
WO2022193186A1 (en) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. New diagnostic and therapeutic agents
US20240165247A1 (en) * 2021-03-17 2024-05-23 Jiangyin Usun Pharmaceutical Co., Ltd. New peptide conjugates
EP4665372A1 (en) * 2023-02-13 2025-12-24 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. New multi-functional oligopeptides
WO2024260465A1 (en) 2023-06-22 2024-12-26 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New multi-functional oligopeptides
WO2025195444A1 (en) 2024-03-20 2025-09-25 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New use of peptides derived from vasoactive intestinal peptide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039128A1 (en) * 1995-06-06 1996-12-12 Hemosphere, Inc. Protein particles for therapeutic and diagnostic use
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
EP1851237A4 (en) * 2005-02-16 2009-01-07 Univ California PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING BONE DISORDERS
EP2101547B1 (de) 2008-03-11 2014-03-05 Vita Zahnfabrik H. Rauter GmbH & Co. KG Dental-Sinterofen sowie Verfahren zum Sintern keramischer Dental-Elemente
JP2012526155A (ja) 2009-08-25 2012-10-25 ポステック アカデミー−インダストリー ファンデーション イガイ接着蛋白質またはその変異体に陰イオン性高分子が含まれたコアセルベート
WO2013167298A1 (en) * 2012-05-11 2013-11-14 Kael-Gemvax Co., Ltd. Anti-inflammatory peptides and composition comprising the same
CN105392468A (zh) * 2013-05-20 2016-03-09 高敏 贻贝粘蛋白凝胶的制备方法、贻贝粘蛋白凝胶及其应用
KR102468519B1 (ko) * 2015-07-20 2022-11-21 장인 벵트 아이. 사무엘손 인스티튜트 오브 라이프 사이언스 컴퍼니 리미티드 피부 염증의 억제에서의 홍합 접착 단백질 제품 및 이의 적용
WO2017028025A1 (zh) 2015-08-14 2017-02-23 江阴市本特塞缪森生命科学研究院有限公司 贻贝粘蛋白产品及其抑制粘膜炎症的应用
WO2017181372A1 (zh) 2016-04-20 2017-10-26 江阴市本特塞缪森生命科学研究院有限公司 贻贝粘蛋白产品及其抑制血管炎症的应用
CN106581656A (zh) * 2016-12-30 2017-04-26 江阴贝瑞森生化技术有限公司 一种用于小儿舌舔皮炎的软膏
WO2019011286A1 (en) * 2017-07-14 2019-01-17 Jiangyin Usun Pharmaceutical Co., Ltd. ANTIVIRAL USE OF MEMBRANE ADHESIVE PROTEINS

Similar Documents

Publication Publication Date Title
JP2021525242A5 (https=)
US20100113503A1 (en) Cycloalkane[b]azaindole antagonists of prostaglandin d2 receptors
CN116785447B (zh) 孟鲁司特与肽的新缀合物
JP2022500437A5 (https=)
US20160030452A1 (en) Minocycline Derivatives
US11518765B2 (en) Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
JPWO2019228307A5 (https=)
RU2020121152A (ru) Твердые формы ингибитора калликреина плазмы и их соли
WO2003086407A1 (de) Verwendung von stimulatoren der löslichen guanylatcyclase zur behandlung von glaukom
JP2022502500A5 (https=)
JP2020503324A (ja) 慢性疼痛の処置のための組成物及び方法
JP2025164962A (ja) ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体
JP2019530674A5 (https=)
JP2015528501A5 (https=)
JP2017522304A5 (https=)
WO2006101858B1 (en) Alpha-helix mimetics and methods relating to the treatment of fibrosis
US20160243081A1 (en) Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
CN113272298A (zh) 用于治疗呼吸系统疾病的化合物和组合物
WO2024088153A1 (zh) 托品酸及其衍生物在制备治疗银屑病药物中的用途
CN112334464B (zh) 丙二酸的双酰胺衍生物用于在人和动物中治疗变应性疾病和其他疾病的用途
CN111700889A (zh) 柚皮素在制备治疗癌症恶病质药物中的应用
US20040019022A1 (en) Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction, damage and injury in mammals
US20220105082A1 (en) New formulations containing leukotriene receptor antagonists
US20110151025A1 (en) Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections
JP2021528479A5 (https=)